In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 10, 2010, Pages 2158-2163

  Spreghini, Elisabetta ^a   Orlando, Fiorenza ^b   Giannini, Daniele ^a   Barchiesi, Francesco ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INRCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; POSACONAZOLE;

ABSIDIA; ANIMAL EXPERIMENT; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; RHIZOPUS ORYZAE; ZYGOMYCETES;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CHILD; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MUCORALES; RHIZOPUS; SURVIVAL ANALYSIS; TETRAZOLIUM SALTS; TREATMENT OUTCOME; TRIAZOLES; ZYGOMYCOSIS;

EID: 77957245496     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq276     Document Type: Article

References (26)

1. Kauffman CA. Zygomycosis: reemergence of an old pathogen. Clin Infect Dis 2004; 39: 588-90.
2. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-53.
3. Spellberg B, Walsh TJ, Kontoyiannis DP et al. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009; 48: 1743-51.
4. Hoffmann K, Discher S, Voigt K. Revision of the genus Absidia (Mucorales, Zygomycetes) based on physiological, phylogenetic, and morphological characters; thermotolerant Absidia spp. form a coherent group, Mycocladiaceae fam. nov. Mycol Res 2007; 111: 1169-83.
5. Almyroudis NG, Sutton DA, Fothergill AWet al. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007; 51: 2587-90.
6. Dannaoui E, Meletiadis J, Mouton JW et al. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003; 51: 45-52.
7. Espinel-Ingroff A, Chaturvedi V, Fothergill A et al. Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J Clin Microbiol 2002; 40: 3776-81.
8. Espinel-Ingroff A, Canton E. Comparison of Neo-Sensitabs tablet diffusion assay with CLSI broth microdilution M38-A and disk diffusion methods for testing susceptibility of filamentous fungi with amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 2008; 46: 1793-803.
9. Keating GM. Posaconazole. Drugs 2005; 65: 1553-67.
10. Lass-Flörl C, Mayr A, Perkhofer S et al. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 2008; 52: 3637-41.
11. Sabatelli F, Patel R, Mann PA et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50: 2009-15.
12. Sun QN, Fothergill AW, McCarthy DI et al. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002; 46: 1581-2.
13. Torres-Narbona M, Guinea J, Martínez-Alarcón J et al. In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. Antimicrob Agents Chemother 2007; 51: 1126-9.
14. Barchiesi F, Spreghini E, Santinelli A et al. Posaconazole prophylaxis in experimental systemic zygomycosis. Antimicrob Agents Chemother 2007; 51: 73-7.
15. Dannaoui E, Meis JF, Loebenberg D et al. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother 2003; 47: 3647-50.
16. Greenberg RN, Mullane K, van Burik JA et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50: 126-33.
17. Ibrahim AS, Gebremariam T, Schwartz JA et al. Posaconazole monoor combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother 2009; 53: 772-5.
18. Rodríguez MM, Pastor FJ, Sutton DA et al. Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. Antimicrob Agents Chemother 2010; 54: 1665-9.
19. Sun QN, Najvar LK, Bocanegra R et al. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother 2002; 46: 2310-2.
20. Van Burik JA, Hare RS, Solomon HS et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42: e61-5.
21. White TJ, Bruns T, Lee S et al. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In: Innis MA, Gelfand DH, Sninsky JJ et al. eds. PCR Protocols: A Guide to Methods and Applications. San Diego: Academic Press, 1990; 315-22.
22. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi-Second Edition: Approved Standard M38-A2. CLSI, Wayne, PA, USA, 2008.
23. Pfaller MA, Sheehan DJ, Rex JH. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin Microbiol Rev 2004; 17: 268-80.
24. Antachopoulos C, Meletiadis J, Roilides E et al. Rapid susceptibility testing of medically important zygomycetes by XTT assay. J Clin Microbiol 2006; 44: 553-60.
25. Simitsopoulou M, Roilides E, Maloukou A et al. Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes. Mycoses 2008; 51: 147-54.
26. Lewis RE, Albert ND, Liao G et al. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrob Agents Chemother 2010; 54: 1298-304.